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Abstract 
To develop a simple, accurate, precision and economical UV-Vis spectrophotometric and mole ratio method for 
the analysis in pharmaceutical formulations by making its complexes with calcium(II) and magnesium(II). In this 
study, the separately spectrums of Valsartan and the complexes occured between Ca2+ and Mg2+ metal ions were 
taken in ultra-violet area. In addition, stoichiometric ratios of the complexes occured between Valsartan with 
Ca2+ and Mg2+ metal ions were determined using mole ratio method. The wavelength of maximum absorption of 
the spectrum Valsartan and metal complexes with Ca(II) and Mg(II) were determined. The experimental data 
indicate the formation of metal:ligand = 1:1 complexes for Ca(II)-Valsartan and Mg(II)-Valsartan. Valsartan’s 
recovery rate, it was found in the range of 92.0– 97.5%. Beer’s obeyed in the concentration range of 2.18 -10.89 
µg/mL for VAL. The LOD and LOQ were found to be 2.21µg/mL and 10.9µg/mL for Valsartan respectively. It is 
considered that the complexes between Valsartan with Ca2+ and Mg2+ metal ions would affect treatments 
positively or negatively. 
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1. Introduction 
Hypertension is the circumstance when the values of diastolic and systolic blood pressure increases above 
normal values. In other words, hypertension is a cardiovascular disease in which the blood pressure rises above 
the normal level. According to the etiology of hypertension, two groups are separated as primary and secondary. 
Primary hypertension accounts for approximately 95% of hypertensive patients but Secondary hypertension 
constitutes approximately 5% of hypertensive patients [1,2,3]. Antihypertansive drugs are used in the treatment 
of hypertension. Angiotensin II (A-II) receptor blockers, emerging as a new class of antihypertensive agents, are 
selective for angiotensin II subtype I (AT1). For instance, Valsartan is an antihypertensive agent and is a member 
of the class of angiotensin II. Valsartan’s chemical name, N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-
valine (Figure 1). It is an angiotensin II receptor blocker which inhibits the known activities of type-1 
angiotensin II receptor. Thus, it provides to decrease high blood pressure to normal levels which causes narrow 
blood vessels to enlarge. It is used in heart failure, hypertension (high blood pressure), systolic hypertension, 
myocardial infraction and left ventricular hypertrophy [4,5,6,7,8,9]. Literature review describes some analytical 
method for Valsartan. However, there is no study of the stoichiometry of metal complexes formed for this drug 
with some metal ions. For this reason, the aim of this work is to develop a simple, fast, accurate and precise UV-
Vis spectrophotometric method to determine the stoichiometric ratios of complexes formed between Valsartan 
and some metal ions. 
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       Figure 1. Chemical structure of Valsartan 
   
2. Experimental 
2.1. Chemical and reagent 
Valsartan was obtained from Sigma-Aldrich Chemical Co. (USA). Calcium nitrate hexahydrate, magnesium 
nitrate hexahydrate, and methanol reagent were purchased from Merck Chemical (Germany). All the chemicals 
and solvents were analytical purity. 
 
2.2. Instrument and apparatus 
In this research study, the spectrophotometric measurements were carried on out using a Shimadzu UV-2550 
UV/Vis double beam Spectrophotometer with 1.0 cm matched quartz cell (Germany). During weighing, Scaltec 
Sba 31 brand analytical balance were used. 
 
2.3. Preparation of stock standard solutions 
 
2.3.1. Valsartan standard stock solutions 
Standard stock solution of 5.0x10-3 M Valsartan was prepared mixture of methanol and water (50:50, v/v) and 
transferred into 50 mL volumetric flask to obtain 5.0x10-3 M of standard stock solution from which desired 
concentrations of stock solutions were prepared. 
 
2.3.2. Cu2+ and Mg2+ standard stock solutions 
0.0590 g Ca(NO3)2.4H2O weighed and mixture dissolved methanol:water (50:50, v/v) and transferred into 50 mL 
volumetric flask to obtain 5.0x10-3 M of standard stock solution from which desired concentrations of stock 
solutions were prepared. In a similar way, 0.0644 g Mg(NO3)2.6H2O weighed and mixture dissolved 
methanol:water (50:50, v/v) and transferred into 50 mL volumetric flask to obtain 5.0x10-3 M of standard stock 
solution from which desired concentrations of stock solutions were prepared. 
 
3. Method 
3.1. Analytical selection of wavelength of Valsartan and metal complexes 
In order to select analytical wavelength, working solution of Valsartan was scanned between 400 nm and 190 
nm. The overlay spectrum of Valsartan was recorded. The maximum wavelength of Valsartan was determined 
249.6 nm (Figure 2).  
Chemistry and Materials Research                                                                                                                                                    www.iiste.org 
ISSN 2224- 3224 (Print) ISSN 2225- 0956 (Online) 
Vol.10 No.5, 2018 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overlay spectra of Valsartan (2,5x10-5 M) 
 
Calcium nitrate tetrahydrate (2.5x10-5 M) and Magnesium nitrate hexahydrate (2.5x10-5 M) with Valsartan 
(2,5x10-5 M) working solutions were mixed in a separately test tubes respectively. Then, in order to select 
maximum analytical wavelengths, working solutions of Valsartan-Ca and Valsartan-Mg complexes were 
scanned between 400 nm and 190 nm and from overlay spectra, the maximum wavelength for both complexes 
was found 249.6 nm (Figure 3 and 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overlay spectra of Valsartan (2,5x10-5 M) 
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Figure 4. Overlay spectra of Valsartan (2,5x10-5 M) 
 
3.2. Determination of complex stoichiomety 
Stoichiometry of the complexes of Ca(II)-VAL and Mg(II)-VAL was determined by using mol ratio method as 
base. For this purpose, a series of standard solution which the mole ratio of Valsartan and metal ions of Mg2+ and 
Ca2+ is between 0-2.5 was prepared in separate test tubes. Then, each solution was mixed in vortex and their 
absorbances of maximum wavelength were measured on UV spectrophotometer, and a graphic was drawn using 
the values between ligand:metal mole ratio and absorbance. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
     Figure 5. Mole ratio method for Ca(II)-VAL complex 
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 Figure 6. Mole ratio method for Mg(II)-VAL complex 
 
4.Validation 
The method was validated interms of accuracy, precision, linearity, LOD and LOQ respectively. 
 
4.1. Linearity and calibration curve 
For linearity and calibration curve, working solutions were prepared at 2.18, 4.4, 6.53, 8.7 and 10.89 µg/mL 
different concentrations respectively The solutions were scanned on spectrophotometer in the UV range 190-400 
nm. The absorption spectrum was recorded at 249.6 nm (Figure 7) and a calibration curve was drawn using the 
values between concentrations and absorbance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 7. Absorption spectras of five different concentrations (2.18 -10.89 µg/mL) of Valsartan 
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     Figure 8. Linearity plot of Valsartan 
 
Table 1. Statistical results of Valsartan’s calibration curve  
Statistical parameters Result 
Wavelength 204 nm  249.6 nm  
Linearity range 2.20-10.89 µg/mL  
Regression linear equation  y=0.1061x+0.006 
r2: Correlation coefficient r2=0.9922 
Sa: Standard deviation on intercept 0.074 
Sb: Standard deviation on slope  1.07 
 
4.2. Precision 
The precision of analytical method, ıntraday and interday measurements were determined by analyzing different 
four solutions (3.5, 5.5, 7.5 and 9.5 µg/mL) of VAL within same day and different three days. The average (x), 
standard deviation (s), percentage relative standard deviation (RSD %) and relative error (BH %) were calculated 
using the values found. 
 
Concentration (µg/mL) 
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Table 2. Intra-day and nter-day precision measurements results. 
Intra-day measurement values Inter-day measurement values 
Known 
value 
µg/mL 
Faound 
value 
µg/mL 
    x̄±s 
  µg/mL BH %  RSD % 
Faound 
value 
µg/mL 
     x̄±s 
   µg/mL BH % RSD % 
3.5 
3.49   
3.51   
3.52  
3.51±0.02 0,29 0.43 
3.77    
3.78     
3.77 
3.77±0.01 7.71 0.27 
5.5 
5.42   
5.40   
5.39 
5.40±0.015 -1,82 0.28 
5.38    
5.41    
5.44 
5.41±0.03 -1.64 0.55 
7.5 
7.32   
7.33   
7.33 
7.33±0.01 -2,27 0.14 
7.32    
7.33    
7.40 
7.35±0.04 -2 0.54 
8.5 
9.28    
9.35    
9.31 
9.31±0.04 -2 0.43 
9.14     
9.18     
9.24 
9.19±0.05 -3.26 0.54 
x̄: Mean, s: Standard deviation, BH: Relative error, RSD: Relative standard deviation 
 
4.3. Accuracy 
Accuracy of the analytical method was assessed by % recovery studies performed at three different levels, that 
is, 80%, 100% and 120 %. Calculated amount of Valsartan from stock solution was added in placebo to obtain 
80%, 100%, 120% of sample solution. Each sample was prepared in thrice each level. The sample solutions were 
measured on spectrophotometer in the UV range 190-400 nm. The absorbances of sample solutions were 
recorded. 
 
Table 3. Recovery studies of Valsartan 
 
Weighed the amounts of VAL 
mg/1 tablet 
Found the amounts of VAL  
(mg/1 tabet)   Recovery % 
80 % 64 62.4 97.5 
100 % 80 77.31 96.64 
120 % 96 88.28 92.0 
Average recovery   95.38 
 
4.4. LOD and LOQ 
Limit of quantification and limit of detection was calculated by the analytical method which based on 
LOD=C+3s and LOQ=C+10s. 
 
5. Result 
The proposed method is based on spectrophotometric and mole ratio method determination of Valsartan with 
metal complexes UV area using mixture methanol and ultrapure water (50:50, v/v) as solvent. Lambert-Beer’s 
obeyed in the concentration range of 2.18-10.89 µg/mL for VAL (Figure 7). The correlation coefficient value 
was found 0.9922 which shows that absorbance of the drug was linear with concentration. The visual 
characteristics such as linearity range, standard deviation on intercept and slope, correlation coefficient and 
regression linear equation were calculated and are summarized in (Table 1).  The percentage recovery was found 
to be in the range of 92.5-97.5 % for VAL. The result of recovery studies are shown in Table 3. The LOD and 
LOQ were found to be 2.21 µg/mL and 10.9 µg/mL for Valsartan respectively. The mean, standard deviation, 
percentage relative error and relative standard deviation were calculated according to the result of ıntra-day and 
inter-day precision measurements and are summarized in (Table 2). The % RSD values for inter-day analysis 
was 0.43, 0.28, 0.14 and 0.43 but the % RSD values for intra-day analysis was found 0.27, 0.55 and 0.54 for 
VAL, respectively (Table 2). As a result, precision of the analytical method was further substantiating. The 
wavelenghts of maximum absorbtion of the spectrum Valsartan and metal complexes with Ca(II) and Mg(II) 
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were determined. The experimental data indicate the formation of metal:ligand = 1:1 complexes for Ca(II)-
Valsartan and Mg(II)-Valsartan (Figure 5 and 6). 
 
6. Conclusion 
In the literature, there is no study on the interaction of Valsartan with calcium(II) and magnesium(II) ions. As a 
result of the study, literature knowledge on the interaction between Valsartan and metal ions were obtained and 
we think that the Valsartan metal interaction will contribute to the literature. 
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